Blocking immune checkpoints in prostate, kidney, and urothelial cancer

An overview

Angela K B Alme, Beerinder S. Karir, Bishoy M. Faltas, Charles G. Drake

Research output: Contribution to journalArticle

Abstract

Despite a long history of immunotherapeutic approaches to treatment, most genitourinary malignancies are not cured by existing immunotherapy regimens. More recently, cell surface molecules known as immune checkpoints have become the focus of efforts to develop more effective immunotherapies. Interactions between these molecules and their ligands inhibit the proliferation and function of tumor-specific lymphocytes. A monoclonal antibody blocking 1 of these checkpoints was approved for the treatment of metastatic melanoma and is now being tested in other malignancies. The objective responses seen in these early trials of checkpoint blockade are driving renewed enthusiasm for cancer immunotherapy. There are several ongoing and planned trials in genitourinary malignancies of single-agent inhibitors, as well as combinations targeting multiple checkpoints or adding other types of therapies to checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)171-181
Number of pages11
JournalUrologic Oncology: Seminars and Original Investigations
Volume34
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Kidney Neoplasms
Prostate
Immunotherapy
Neoplasms
Melanoma
Therapeutics
Monoclonal Antibodies
Lymphocytes
Ligands

Keywords

  • Bladder cancer
  • CTLA-4
  • Kidney cancer
  • LAG-3
  • PD-1
  • PD-L1
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Blocking immune checkpoints in prostate, kidney, and urothelial cancer : An overview. / Alme, Angela K B; Karir, Beerinder S.; Faltas, Bishoy M.; Drake, Charles G.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 34, No. 4, 01.04.2016, p. 171-181.

Research output: Contribution to journalArticle

Alme, Angela K B ; Karir, Beerinder S. ; Faltas, Bishoy M. ; Drake, Charles G. / Blocking immune checkpoints in prostate, kidney, and urothelial cancer : An overview. In: Urologic Oncology: Seminars and Original Investigations. 2016 ; Vol. 34, No. 4. pp. 171-181.
@article{62383927b2ce49deb642222907ff0962,
title = "Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview",
abstract = "Despite a long history of immunotherapeutic approaches to treatment, most genitourinary malignancies are not cured by existing immunotherapy regimens. More recently, cell surface molecules known as immune checkpoints have become the focus of efforts to develop more effective immunotherapies. Interactions between these molecules and their ligands inhibit the proliferation and function of tumor-specific lymphocytes. A monoclonal antibody blocking 1 of these checkpoints was approved for the treatment of metastatic melanoma and is now being tested in other malignancies. The objective responses seen in these early trials of checkpoint blockade are driving renewed enthusiasm for cancer immunotherapy. There are several ongoing and planned trials in genitourinary malignancies of single-agent inhibitors, as well as combinations targeting multiple checkpoints or adding other types of therapies to checkpoint blockade.",
keywords = "Bladder cancer, CTLA-4, Kidney cancer, LAG-3, PD-1, PD-L1, Prostate cancer",
author = "Alme, {Angela K B} and Karir, {Beerinder S.} and Faltas, {Bishoy M.} and Drake, {Charles G.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.urolonc.2016.01.006",
language = "English (US)",
volume = "34",
pages = "171--181",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Blocking immune checkpoints in prostate, kidney, and urothelial cancer

T2 - An overview

AU - Alme, Angela K B

AU - Karir, Beerinder S.

AU - Faltas, Bishoy M.

AU - Drake, Charles G.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Despite a long history of immunotherapeutic approaches to treatment, most genitourinary malignancies are not cured by existing immunotherapy regimens. More recently, cell surface molecules known as immune checkpoints have become the focus of efforts to develop more effective immunotherapies. Interactions between these molecules and their ligands inhibit the proliferation and function of tumor-specific lymphocytes. A monoclonal antibody blocking 1 of these checkpoints was approved for the treatment of metastatic melanoma and is now being tested in other malignancies. The objective responses seen in these early trials of checkpoint blockade are driving renewed enthusiasm for cancer immunotherapy. There are several ongoing and planned trials in genitourinary malignancies of single-agent inhibitors, as well as combinations targeting multiple checkpoints or adding other types of therapies to checkpoint blockade.

AB - Despite a long history of immunotherapeutic approaches to treatment, most genitourinary malignancies are not cured by existing immunotherapy regimens. More recently, cell surface molecules known as immune checkpoints have become the focus of efforts to develop more effective immunotherapies. Interactions between these molecules and their ligands inhibit the proliferation and function of tumor-specific lymphocytes. A monoclonal antibody blocking 1 of these checkpoints was approved for the treatment of metastatic melanoma and is now being tested in other malignancies. The objective responses seen in these early trials of checkpoint blockade are driving renewed enthusiasm for cancer immunotherapy. There are several ongoing and planned trials in genitourinary malignancies of single-agent inhibitors, as well as combinations targeting multiple checkpoints or adding other types of therapies to checkpoint blockade.

KW - Bladder cancer

KW - CTLA-4

KW - Kidney cancer

KW - LAG-3

KW - PD-1

KW - PD-L1

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84961208099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961208099&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.01.006

DO - 10.1016/j.urolonc.2016.01.006

M3 - Article

VL - 34

SP - 171

EP - 181

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -